HG-12-6

• CAT Number: I017154
• CAS Number: 2222354-57-4
• Molecular Formula: C₂₉H₂₇F₃N₆O₂S
• Molecular Weight: 580.62
• Purity: ≥95%
• Target: IRAK
• IUPAC Name: 3-[2-(cyclopropanecarbonylamino)-[1,3]thiazolo[5,4-b]pyridin-5-yl]-N-[4-(piperazin-1-ylmethyl)-3-(trifluoromethyl)phenyl]benzamide
• InChI: InChI=1S/C29H27F3N6O2S/c30-29(31,32)22-15-21(7-6-20(22)16-38-12-10-33-11-13-38)34-26(40)19-3-1-2-18(14-19)23-8-9-24-27(35-23)41-28(36-24)37-25(39)17-4-5-17/h1-3,6-9,14-15,17,33H,4-5,10-13,16H2,(H,34,40)(H,36,37,39)
• InChIKey: BBTDRPBKISKELY-UHFFFAOYSA-N
• SMILES: C1CC1C(=O)NC2=NC3=C(S2)N=C(C=C3)C4=CC(=CC=C4)C(=O)NC5=CC(=C(C=C5)CN6CCNCC6)C(F)(F)F

HG-12-6（Cat No.:I017154）is a small molecule inhibitor that targets and inhibits the activity of the protein kinase GSK-3β (Glycogen Synthase Kinase-3 beta), an enzyme involved in regulating various cellular processes, including cell cycle, apoptosis, and metabolism. By inhibiting GSK-3β, HG-12-6 has shown potential in preclinical studies for treating conditions such as Alzheimer’s disease, cancer, and other neurodegenerative disorders, where abnormal GSK-3β activity plays a role in disease progression. Research is ongoing to evaluate its efficacy, safety, and therapeutic potential in clinical trials, particularly for neurodegenerative diseases and oncology.